Reata’s pivotal data in Friedreich ataxia point to submissions

By Sandi Wong, Staff Writer | Oct 14, 2019 | 10:22 PM GMT
Editor's note: Updated on Oct 14, 2019 at 10:25 PM GMT

Days after regaining worldwide rights to omaveloxolone, Reata announced plans to submit regulatory applications in the U.S. and other territories for the compound in Friedreich ataxia based on newly released pivotal trial data.

Reata Pharmaceuticals

Read the full 348 word article

How to gain access

Continue reading with a
two-week free trial.